# US 8,277,815 B2 · Pharmaceutical composition comprising an antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,815 B2
- Document ID: US8277815B2
- Status: Granted
- Kind: B2
- Application number: 13/110,454
- Filed: 2011-05-18
- Published: 2011-12-08
- Granted: 2012-10-02
- Earliest claimed: 1999-10-01
- Assignees: Intercell AG
- Inventors: Michael Buschle; Julia-Kristina Fleitmann; Frank Mattner; Jack Melling
- Web page: https://patentgrep.com/patent/US8277815B2

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/29: Hepatitis virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55583: {Polysaccharides}
- C12N 2710/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.

## Claims

### Claim 1

An immunogenic composition comprising an isolated HCV antigen consisting of SEQ ID NO: 1 and a polycationic compound.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the polycationic compound is a basic polypeptide, an organic polycation, a basic polyaminoacid or a mixture of such compounds.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the polycationic compound comprises polyarginine, polylysine, a polypeptide of more than 8 amino acids containing more than 50% basic amino acid residues, or a mixture of such compounds.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the polycationic compound comprises a polypeptide of more than 20 amino acids containing more than 50% basic amino acid residues.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the polycationic compound is polyarginine.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising an additional immunostimulating compound.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the additional immunostimulating compound is selected from the group consisting of growth hormones, human growth hormones, neurokinin A, vasoactive intestinal peptide, neuropeptide Y, substance P, thyrotrophin (TSH), insulin-like growth factor I (IGF-1), prolactin, lactogen, luteinizing hormone, follicle stimulating hormone, dehydroepiandrosterone (DHEA), thymosin, thymulin, kentsin, melatonin, semaphorins, and a mixture of such compounds.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising a stabilizer.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition is in liquid form.

### Claim 10 (depends on 1)

A method of inducing an immune response against HCV in a subject comprising administering to the subject the composition of claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is administered via a route selected from the group consisting of subcutaneous, intramuscular, intradermal, transdermal injection, and oral uptake.

### Claim 12 (depends on 10)

The method of claim 10, wherein the composition is administered to a subject at weekly, bi-weekly or monthly intervals.

### Claim 13 (depends on 1)

A method of inducing an immune response against HCV in a subject comprising administering to the subject the composition of claim 1 and an additional immunostimulating compound, wherein the additional immunostimulating compound is administered separately from the composition of claim 1.

### Claim 14 (depends on 1)

A kit comprising:
a component comprising the composition of claim 1; and
a component comprising an additional immunostimulating compound.
